Bioidentical hormone therapy uses hormones that are chemically identical to the ones your body produces naturally. The goal is to replace hormones that decline during menopause, perimenopause, or other conditions that cause hormonal imbalances, relieving symptoms like hot flashes, night sweats, sleep problems, and vaginal dryness. These hormones come in both FDA-approved pharmaceutical products and custom-compounded preparations, and the distinction between the two matters more than most people realize.
How Bioidentical Hormones Differ From Synthetic Ones
The word “bioidentical” describes a hormone whose chemical structure is an exact match to what the human body makes. Estradiol, progesterone, and testosterone are the most commonly used bioidentical hormones. Because the molecular structure is identical to what your cells already recognize, the idea is that the body processes and responds to them the same way it would its own hormones.
Conventional hormone therapy, by contrast, often uses hormones that are close but not structurally identical. Conjugated equine estrogens, derived from pregnant horse urine, contain a mix of estrogens whose effects at the genetic level differ from human estradiol. Synthetic progestins like medroxyprogesterone acetate behave differently from bioidentical progesterone in several important ways, including how they affect breast cancer risk and cardiovascular health. These aren’t just academic distinctions. The type of progestogen used in combined hormone therapy significantly influences the risk profile, with synthetic progestins like norethisterone linked to higher increases in breast cancer risk compared to options closer to the body’s own hormones.
What It Treats
Bioidentical hormone therapy is primarily used for symptoms tied to dropping estrogen and progesterone levels during perimenopause and menopause. The North American Menopause Society considers hormone therapy the most effective treatment for vasomotor symptoms (hot flashes and night sweats) and has confirmed it prevents bone loss and fracture. Common symptoms people seek treatment for include:
- Hot flashes and night sweats
- Vaginal dryness and painful intercourse
- Sleep disruption
- Low energy and fatigue
- Mood changes and brain fog
- Loss of interest in sex
- Weight gain
For women under 60 or within 10 years of menopause onset, the benefit-to-risk ratio is favorable. For those starting more than 10 years after menopause or over age 60, the risks of heart disease, stroke, blood clots, and dementia increase, making the decision more nuanced.
FDA-Approved vs. Compounded Products
This is where bioidentical hormone therapy gets confusing, because the term covers two very different categories of products. Many people hear “bioidentical” and assume it means custom-made at a compounding pharmacy. In reality, dozens of FDA-approved medications already use bioidentical hormones. Estradiol patches (Climara, Vivelle-Dot, Minivelle), estradiol gels (Divigel, EstroGel), estradiol pills (Estrace), and micronized progesterone capsules (Prometrium) are all bioidentical and all FDA-approved. They’ve gone through rigorous testing for purity, potency, safety, and effectiveness.
Compounded bioidentical hormone therapy (cBHT) is a different story. These are custom-mixed by compounding pharmacies into capsules, creams, gels, pellets, or injections tailored to an individual’s prescription. They are not FDA-approved, which means they don’t carry labeling about risks and side effects, haven’t been tested for bioequivalence with approved products, and aren’t held to the same manufacturing standards. The lack of standardization increases the risk of getting too much, too little, or a contaminated product. Compounded progesterone capsules, for example, haven’t been tested for dose proportionality with FDA-approved versions.
No evidence supports the claim that compounded bioidentical hormones are superior to FDA-approved hormone therapy. That doesn’t mean compounding has no role. Sometimes a patient needs a specific dose or delivery form that isn’t commercially available. But the marketing around compounded hormones often overstates benefits and understates risks.
Delivery Methods and How They Compare
Bioidentical hormones come in several forms, each with trade-offs in convenience, absorption, and safety.
Patches are applied to the skin weekly or twice weekly. They bypass the liver entirely, which is a meaningful advantage: transdermal estrogen doesn’t increase blood clot risk the way oral estrogen does. Patches are often the preferred starting point for that reason.
Gels, creams, and sprays are applied to the skin daily. They share the clotting advantage of patches since they’re also absorbed through the skin, but absorption can be inconsistent, sometimes not delivering the full prescribed dose.
Pills are taken daily and are the most familiar form. The main drawback is that oral estrogen passes through the liver first, which affects clotting factors and raises the risk of blood clots compared to transdermal options.
Vaginal products (creams, tablets, rings, suppositories) deliver estrogen locally and are effective in low doses for vaginal dryness and urinary symptoms without significant absorption into the rest of the body. Rings are replaced every three months, while other vaginal products need daily or twice-weekly application.
Pellets are small hormone implants placed under the skin, typically replaced every three to four months. They’re compounded products, not FDA-approved, and absorption varies considerably from person to person. Because they can’t be removed easily once implanted, dosing problems are harder to correct.
Hormone Testing for BHRT
Providers use blood tests, saliva tests, or sometimes urine tests to measure hormone levels before and during treatment. Blood testing is the standard in most clinical settings. Saliva testing has some evidence supporting its accuracy for measuring biologically active hormone levels, and proponents argue it reflects what’s actually available to your tissues rather than total hormone circulating in the blood. Still, many physicians favor blood testing because of its longer track record and established reference ranges. Be cautious of any provider who insists on expensive, proprietary testing panels as a prerequisite for treatment.
Costs and Insurance Coverage
The cost of bioidentical hormone therapy ranges widely, from under $10 to over $500 per month depending on the product, brand vs. generic, and insurance coverage. Most FDA-approved hormone therapy is covered by private insurance, Medicare Part D, and many state Medicaid programs. Generic estradiol patches can cost under $40 a month with insurance. Generic pills and progesterone capsules often run less than $50 for a 30-day supply.
Compounded products and pellets are generally not covered by insurance. Pellet therapy averages about $1,500 per year out of pocket. Testosterone therapy for women, which is prescribed off-label since no FDA-approved testosterone product exists for women, typically costs $45 to $100+ per month and isn’t covered by insurance either.
Risks and Safety Considerations
Bioidentical hormones carry real risks that vary by type, dose, how they’re delivered, and how long you use them. The risks are not eliminated simply because the hormones match your body’s own chemistry. Estrogen therapy increases the risk of blood clots, particularly in oral form. Combined estrogen-progesterone therapy has been linked to a small increase in breast cancer risk that grows with duration of use, though the type of progesterone matters. Bioidentical micronized progesterone appears to carry a lower breast cancer risk than synthetic progestins like medroxyprogesterone and norethisterone.
Timing matters significantly. Starting hormone therapy close to menopause onset, ideally within 10 years, carries a much more favorable risk profile than starting later. The North American Menopause Society recommends individualized treatment with periodic reassessment of whether the benefits still outweigh the risks. Longer use should be tied to ongoing symptoms that justify continued therapy, not open-ended prescribing.
Route of delivery also shifts the risk equation. Transdermal estrogen (patches, gels, sprays) avoids the liver’s first-pass metabolism and does not appear to increase clotting risk the way oral estrogen does. For women with elevated clot risk, obesity, or a history of migraines, transdermal delivery is generally the safer choice.